|
Pfizer Hopes Pipeline Will Overflow Soon, With Five Potential New Products This Year
Despite being battered by recent generic competition for key products, Pfizer executives and analysts expect the company to rebound big time later this year with a spate of new product approvals.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives